Pharma Reviews
Pages
Home
Pharma News
US FDA News
Pharma Jobs
Thursday, June 2, 2016
US FDA News: Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars
Reports of severe redness, pain, skin discoloration, blistering, and cracked skin.
Read more:
Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars
Newer Post
Older Post
Home
View mobile version